Emerging Stocks Down Under 26 April 2022: Invex Therapeutics (ASX:IXC)
Invex Therapeutics: A biotech taking a shortcut to marketDrug development and commercialisation typically takes several years but Invex Therapeutics (ASX:IVX) is taking a shortcut to market. It is repurposing a drug already on market for a different condition, namely Presendin (a drug conventionally used to treat diabetes) for neurological conditions caused by intracranial pressure. The company is about to start a Phase 3 clinical trial and - if all goes to plan - commercialise the drug by 2025 when it will have patent protection for a decade thereafter. Click here to read the previous edition of Emerging Stocks Down Under published 19 April 2022 For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.
Please register or upgrade your plan to access this content.